KINSHASA, DR CONGO / RankWire.AI / – As the Ebola outbreak in the Democratic Republic of the Congo continues to intensify, the country has been allocated 70,000 Ervebo Ebola vaccine doses. The outbreak has led to a total of 5,208 confirmed cases and 2,476 fatalities reported by Congolese authorities as of Aug. 18. The epidemic now spans 56 health zones across six provinces situated in the eastern and northeastern regions. Authorities have also recorded 1,115 recoveries, while 730 patients remain hospitalized or in isolation.
Following the government’s request for additional doses from the global Ebola stockpile, the International Coordinating Group on Vaccine Provision approved their release. The World Health Organization (WHO) stated that 20,000 doses will be used in a Phase 3 clinical trial focusing on Bundibugyo virus disease, while the remaining 50,000 doses are designated for frontline and healthcare workers in accordance with current vaccination guidelines. The allocation was announced on Aug. 20, and both WHO and Africa CDC expressed their support for this decision.
Ervebo holds licensing for Ebola virus outbreaks, formerly known as Zaire ebolavirus, but it lacks specific approval for Bundibugyo virus disease. Laboratory and animal studies indicate potential cross-protection, yet the level of protection in humans remains uncertain. The upcoming clinical trial aims to evaluate the vaccine’s effectiveness during the ongoing outbreak and contribute valuable evidence for future public health strategies. WHO has emphasized that recipients should be informed about known risks, possible benefits, and the current limitations of the vaccine.
Outbreak Extends Across Six Provinces in Congo
The outbreak originated in the Mongbwalu health zone within Ituri Province, with confirmation by Congolese authorities in May. Since then, cases have spread to North Kivu, South Kivu, Haut-Uele, Tshopo, and Bas-Uele. By Aug. 12, WHO recorded 4,665 cases and 2,184 deaths across 54 health zones. Updated national figures later increased those totals to 5,208 cases, 2,476 deaths, and 56 affected zones. The current case fatality ratio stands at 47.5%.
WHO has characterized the outbreak as the largest Ebola epidemic ever documented in DR Congo. It has also reported intense transmission, with cases and fatalities continuing to rise across interconnected areas. Challenges such as insecurity, population displacement, and extensive movement along roads and trade routes have hindered surveillance efforts and access to patients. In response, teams are expanding treatment facilities, strengthening disease monitoring, tracing contacts, and ensuring safe burials. Meanwhile, Congolese health authorities have increased their capacity to provide care in affected regions.
Vaccine Distribution Supports Public Health and Research Initiatives
Gavi, the Vaccine Alliance, pledged $7 million to finance the shipment of 70,000 Ervebo doses. An additional $6 million has been allocated through its First Response Fund to support routine immunization efforts and Ebola vaccination readiness. The global Ebola stockpile is managed via the International Coordinating Group with assistance from multiple partner organizations, including WHO, UNICEF, the International Federation of Red Cross and Red Crescent Societies, and Médecins Sans Frontières. Gavi’s funding plays a critical role in maintaining the vaccine stockpile.
DR Congo officially declared the outbreak on May 15, following laboratory confirmation of Bundibugyo virus disease. WHO responded by declaring a public health emergency of international concern on May 17. Since there is no licensed vaccine or specific treatment for Bundibugyo virus disease, supportive care and early detection are vital components of the response. WHO continues to support surveillance efforts, clinical management, supply distribution, contact tracing, and community engagement across affected provinces. The recent allocation of 70,000 doses enhances vaccination efforts and supports ongoing research alongside other public health measures.